<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447446</url>
  </required_header>
  <id_info>
    <org_study_id>MV25599</org_study_id>
    <nct_id>NCT01447446</nct_id>
  </id_info>
  <brief_title>An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C</brief_title>
  <official_title>Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This prospective, multicenter, observational cohort study will evaluate the efficacy and
      safety of pegylated interferon alfa (peginterferon alfa) (e.g. Pegasys) plus ribavirin and
      treatment regimens containing direct-acting antivirals in participants with chronic hepatitis
      C who are treatment-na√Øve or treatment-experienced and HIV HCV co-infected. Data will be
      collected from participants receiving treatment according to current Summary of Product
      Characteristics (SPC) and local labeling for the duration of their treatment and a 24-week
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virological Response at 24 Weeks Post Completion of the Treatment Period (SVR24)</measure>
    <time_frame>24 weeks after end of treatment (up to 118 weeks)</time_frame>
    <description>SVR24 rate for dual therapy participants is defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (&lt;) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [&lt;=] 50 IU/mL) at 24 weeks post completion of the treatment period. If a quantitative test was used, the lower limit of quantification had to be &lt;=50 IU/mL. SVR24 for triple therapy participants is defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection &lt;= 50 IU/mL at 24 weeks post completion of the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virological Response at 12 Weeks Post Completion of the Treatment Period (SVR12)</measure>
    <time_frame>12 weeks after end of treatment (up to 118 weeks)</time_frame>
    <description>SVR12 rate for dual therapy participants is defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (&lt;) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [&lt;=] 50 IU/mL) at 12 weeks post completion of the treatment period. If a quantitative test was used, the lower limit of quantification had to be &lt;=50 IU/mL. SVR12 for triple therapy participants is defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection &lt;= 50 IU/mL at 12 weeks post completion of the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological Response at Various on Treatment Time Points and End of Treatment (EOT)</measure>
    <time_frame>Week 4, 12 and End of treatment (EOT) (up to 96 weeks)</time_frame>
    <description>Virological response (VR) for dual therapy participants is defined as HCV RNA &lt;50 IU/mL as assessed by a qualitative HCV RNA test with a lower limit of detection (LLD) &lt;=50 IU/mL or as assessed by a quantitative test with a lower limit of quantification (LLQ) &lt;=50 IU/mL for all time points concerned. Results of HCV RNA tests with LLD and LLQ &gt;50 IU/mL were considered as non-response. VR for triple therapy participants is defined as undetectable HCV RNA assessed by a test with lower limit of detection &lt;=50 IU/mL (UVR). Results of HCV RNA tests with an LLD &gt;50 IU/mL were considered as non-response for triple therapy participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological Relapse After End of Treatment</measure>
    <time_frame>Up to 24 weeks after EOT (up to 118 weeks)</time_frame>
    <description>Virological relapse defined as non-virological response (non-VR)/non-undetectable virological response (non-UVR) at the last HCV RNA assessment during the treatment-free follow-up period in participants with VR/UVR at EOT. Here, number of participants analyzed is the participants with end of treatment response (EoT-R) who also had an HCV RNA test at least 12 weeks after EoT or whose last follow-up HCV RNA test showed non-response (HCV RNA &gt;=50 IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological Breakthrough</measure>
    <time_frame>Up to EOT (up to 118 weeks)</time_frame>
    <description>Virological breakthrough/rebound defined as non-VR/non-UVR during the treatment period (including end of treatment) in participants with prior VR/UVR or an increase of HCV RNA by &gt;=1 log10 during the treatment period in comparison to the lowest HCV RNA (nadir) previously measured during the treatment period in participants without VR/UVR during the treatment period. Here, Number of participants analyzed is the participants with at least 2 on-treatment HCV RNA assessments (including EoT) or 1 on-treatment HCV RNA assessment (excluding EoT) and response at EoT by backward imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virological Response (SVR) in Participants With Dose Reductions or Treatment Interruptions</measure>
    <time_frame>Up to first 12 weeks of treatment</time_frame>
    <description>SVR 12 and 24 rates for dual therapy participants are defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (&lt;) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [&lt;=] 50 IU/mL) at 12 or 24 weeks post completion of the treatment period. If a qualitative test was used, then the lower limit of detection has to be &lt;=50 IU/mL. SVR12 and 24 rates for triple therapy participants are defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection &lt;= 50 IU/mL at 12 or 24 weeks post completion of the treatment period. Here, number of participants analyzed excluded the participants with premature withdrawal due to lack of efficacy or non-safety reasons and participants without dose reductions or interruptions during the first 99 study days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Very Rapid Virological Response, Rapid Virological Response, Complete Early Virological Response and Partial Early Virological Response (pEVR) During First 12 Weeks</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Percentage of participants with very rapid virological response (VRVR) (defined as VR/UVR by study week 2), rapid virological response (RVR) (defined as VR/UVR by study week 4, but no VRVR), complete early virological response (cEVR) (defined as VR/UVR by study week 12, but no VRVR or RVR) and partial early virological response (pEVR) (defined as a 2 log10 drop of HCV RNA by study week 12, but no VRVR, RVR or cEVR) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Extended (Rapid) Virological Response (eRVR)</measure>
    <time_frame>Up to 98 weeks</time_frame>
    <description>Extended (rapid) virological response (eRVR) defined as UVR at weeks 4 and 12 for telaprevir, and as UVR at weeks 8 and 24 for boceprevir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Treatment</measure>
    <time_frame>Up to 118 weeks</time_frame>
    <description>Duration of overall treatment was defined as the time between first and last administration of any study drug, in weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Treated According to Label/Summary of Product Characteristics (SPC)</measure>
    <time_frame>Up to 118 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued Treatment With PEG-IFN and Ribavirin (RBV)</measure>
    <time_frame>Up to 72 weeks of treatment</time_frame>
    <description>Participants who prolonged the treatment period from 72 weeks were not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued Treatment With Direct-Acting Anti-viral (DAA)</measure>
    <time_frame>Up to 72 weeks of treatment</time_frame>
    <description>Participants who prolonged the treatment period from 72 weeks were not reported. Participants who discontinued their treatment as planned were included. Here, number of participant analyzed is the total number of participants who received direct-acting anti-viral (DAA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Concomitant Medical Condition at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AE)</measure>
    <time_frame>Up to 118 weeks</time_frame>
    <description>An AE was defined as any adverse medical event that occurred after the participant used the investigational medicinal product (IMP) or other intervention behaviors specified by the protocol in the clinical trial regardless of relationship to the study treatment.</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">4442</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
    <description>Participants with chronic hepatitis C (CHC) receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed up for the duration of their treatment and for up to 24 weeks after therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
    <description>Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
    <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
    <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
    <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
    <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFN Alfa-2a</intervention_name>
    <description>Peg-IFN Alfa-2a according to standard of care and in line with local labeling.</description>
    <arm_group_label>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFN Alfa-2b</intervention_name>
    <description>Peg-IFN Alfa-2b according to standard of care and in line with local labeling.</description>
    <arm_group_label>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
    <arm_group_label>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
    <arm_group_label>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin according to standard of care and in line with local labeling.</description>
    <arm_group_label>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
    <arm_group_label>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
    <arm_group_label>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir</intervention_name>
    <description>Boceprevir according to standard of care and in line with local labeling.</description>
    <arm_group_label>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <description>Telaprevir according to standard of care and in line with local labeling.</description>
    <arm_group_label>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</arm_group_label>
    <arm_group_label>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis C (CHC) participants (na√Øve or treatment experienced, including HIV HCV
        co-infected) receiving combination therapy with pegylated interferons plus ribavirin or
        treatment regimens containing direct-acting antivirals.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (according to local legislation) participants

          -  Chronic hepatitis C (HCV)

          -  Naive or treatment experienced, HIV-HCV co-infected or HCV mono-infected

          -  Receiving treatment for HCV with pegylated interferons plus ribavirin or regimens
             containing direct-acting antivirals (DAA) according to standard of care and in line
             with current SPC/local labeling

        Exclusion Criteria:

          -  Contraindications according to SPC/local labeling

          -  Treatment started &gt;4 weeks before entering study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bouge</city>
        <zip>5004</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1190</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gilly (Charleroi)</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heusy</city>
        <zip>4802</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Li√®ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montignies sur Sambre</city>
        <zip>6061</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <zip>0</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cairo</city>
        <zip>0</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kohtla-J√§rve</city>
        <zip>31025</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>P√§rnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aix En Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beziers</city>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bourgoin Jallieu</city>
        <zip>38300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chambray Les Tours</city>
        <zip>37171</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creil</city>
        <zip>60109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Epinay-Sur-Seine</city>
        <zip>93806</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evry</city>
        <zip>91014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freyming Merlebach</city>
        <zip>57804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gonesse</city>
        <zip>95503</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grasse</city>
        <zip>06130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyeres</city>
        <zip>83407</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lagny Sur Marne</city>
        <zip>77405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lomme</city>
        <zip>59462</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <zip>84100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pau</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Laurent Du Var</city>
        <zip>06700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villeneuve Maguelone</city>
        <zip>34751</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villeneuve St Georges</city>
        <zip>94195</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10243</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10777</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burghausen</city>
        <zip>84489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>D√ºsseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kassel</city>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>K√∂ln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>L√ºbeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rottenburg</city>
        <zip>72108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>T√ºbingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11522</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ioannina</city>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larissa</city>
        <zip>41 110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nea Kifissia</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Patra</city>
        <zip>265 04</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ajka</city>
        <zip>H-8400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1067</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1126</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>H-1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>H-4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <zip>H-3501</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ny√≠regyh√°za</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sopron</city>
        <zip>9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sz√©kesfeh√©rv√°r</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tatab√°nya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8901</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chieti</city>
        <state>Abruzzo</state>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Calabria</city>
        <state>Calabria</state>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avellino</city>
        <state>Campania</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gragnano</city>
        <state>Campania</state>
        <zip>80054</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marcianise</city>
        <state>Campania</state>
        <zip>81025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nocera Inferiore</city>
        <state>Campania</state>
        <zip>84014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nola</city>
        <state>Campania</state>
        <zip>80035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <state>Emilia-Romagna</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piacenza</city>
        <state>Emilia-Romagna</state>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savona</city>
        <state>Liguria</state>
        <zip>17100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busto Arsizio</city>
        <state>Lombardia</state>
        <zip>21052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrette Di Ancona</city>
        <state>Marche</state>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Biella</city>
        <state>Piemonte</state>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuorgn√® (TO)</city>
        <state>Piemonte</state>
        <zip>10082</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omegna (VB)</city>
        <state>Piemonte</state>
        <zip>28887</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <state>Puglia</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bisceglie</city>
        <state>Puglia</state>
        <zip>70052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Castellana Grotte</city>
        <state>Puglia</state>
        <zip>70013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Puglia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Messina</city>
        <state>Sicilia</state>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arezzo</city>
        <state>Toscana</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Livorno</city>
        <state>Toscana</state>
        <zip>57124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safat</city>
        <zip>13041</zip>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baabda</city>
        <zip>50</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beirut</city>
        <zip>11-236</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beirut</city>
        <zip>99999</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nabatieh</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tripoli</city>
        <zip>371 Tripoli</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Casablanca</city>
        <zip>20000</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Casablanca</city>
        <zip>20100</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fes</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marrakech</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rabat</city>
        <zip>504</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rabat</city>
        <zip>62000</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muscat</city>
        <zip>P.O Box 35</zip>
        <country>Oman</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Faisalabad</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gujranwala</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lahore</city>
        <zip>20021</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rawalpindi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almada</city>
        <zip>2805-267</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amadora</city>
        <zip>2700-020</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aveiro</city>
        <zip>3810-096</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beja</city>
        <zip>7801-849</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3041-801</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1349-019</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Doha</city>
        <zip>P.O.Box 3051</zip>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-napoca</city>
        <zip>400162</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <zip>700554</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <zip>700620</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <zip>300167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holy Makkah</city>
        <zip>21583-Makkah P.O.Box-53356</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riyadh</city>
        <zip>11159</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>G√§vle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlstad</city>
        <zip>65185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aleppo</city>
        <zip>6448</zip>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>00833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adana</city>
        <zip>01100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06290</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hatay</city>
        <zip>31040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>ISTANBULt</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mersin</city>
        <zip>33169</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokat</city>
        <zip>60250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Al Ain</city>
        <zip>P.O.Box 1006</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dubai</city>
        <zip>4545</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sharjah</city>
        <zip>P.O.Box: 5735 - Sharjah, UAE</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Kuwait</country>
    <country>Lebanon</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Morocco</country>
    <country>Oman</country>
    <country>Pakistan</country>
    <country>Portugal</country>
    <country>Qatar</country>
    <country>Romania</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Syrian Arab Republic</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <results_first_submitted>September 27, 2016</results_first_submitted>
  <results_first_submitted_qc>February 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2017</results_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 4442 participants were enrolled in the study, one participant had double enrollment. Out of 4442 participants, analyses were restricted to only core population, which included 4100 participants.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
          <description>Participants with CHC receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="P2">
          <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
          <description>Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="P3">
          <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="P4">
          <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="P5">
          <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="P6">
          <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2312">Started means participants who started treatment and included in core population.</participants>
                <participants group_id="P2" count="496"/>
                <participants group_id="P3" count="292"/>
                <participants group_id="P4" count="93"/>
                <participants group_id="P5" count="821"/>
                <participants group_id="P6" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1590">Completed means the participants who completed the 24- weeks of follow-up period.</participants>
                <participants group_id="P2" count="331">Insuff.=Insufficient VR= Virological response TRT.=Treatment SVR= Sustained Virological Response</participants>
                <participants group_id="P3" count="192"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="610"/>
                <participants group_id="P6" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="722"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="211"/>
                <participants group_id="P6" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Return/Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="357"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="69"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insuff. VR/TRT too Short to Expect VR</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative/Other</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>SVR12 Assessment</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New Treatment Started</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
      <group_list>
        <group group_id="B1">
          <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
          <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="B2">
          <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
          <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="B3">
          <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="B4">
          <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="B5">
          <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="B6">
          <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2312"/>
            <count group_id="B2" value="496"/>
            <count group_id="B3" value="292"/>
            <count group_id="B4" value="93"/>
            <count group_id="B5" value="821"/>
            <count group_id="B6" value="86"/>
            <count group_id="B7" value="4100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less Than or Equal to (&lt;=) 45 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="987"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="184"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="1457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater (&gt;) 45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1325"/>
                    <measurement group_id="B2" value="318"/>
                    <measurement group_id="B3" value="219"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="637"/>
                    <measurement group_id="B6" value="72"/>
                    <measurement group_id="B7" value="2643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="910"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="331"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="1679"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1402"/>
                    <measurement group_id="B2" value="246"/>
                    <measurement group_id="B3" value="184"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="490"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="2421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virological Response at 24 Weeks Post Completion of the Treatment Period (SVR24)</title>
        <description>SVR24 rate for dual therapy participants is defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (&lt;) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [&lt;=] 50 IU/mL) at 24 weeks post completion of the treatment period. If a quantitative test was used, the lower limit of quantification had to be &lt;=50 IU/mL. SVR24 for triple therapy participants is defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection &lt;= 50 IU/mL at 24 weeks post completion of the treatment period.</description>
        <time_frame>24 weeks after end of treatment (up to 118 weeks)</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virological Response at 24 Weeks Post Completion of the Treatment Period (SVR24)</title>
          <description>SVR24 rate for dual therapy participants is defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (&lt;) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [&lt;=] 50 IU/mL) at 24 weeks post completion of the treatment period. If a quantitative test was used, the lower limit of quantification had to be &lt;=50 IU/mL. SVR24 for triple therapy participants is defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection &lt;= 50 IU/mL at 24 weeks post completion of the treatment period.</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2312"/>
                <count group_id="O2" value="496"/>
                <count group_id="O3" value="292"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="821"/>
                <count group_id="O6" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" lower_limit="50.1" upper_limit="54.2"/>
                    <measurement group_id="O2" value="49.4" lower_limit="44.9" upper_limit="53.9"/>
                    <measurement group_id="O3" value="46.6" lower_limit="40.7" upper_limit="52.5"/>
                    <measurement group_id="O4" value="50.5" lower_limit="40.0" upper_limit="61.1"/>
                    <measurement group_id="O5" value="57.7" lower_limit="54.3" upper_limit="61.1"/>
                    <measurement group_id="O6" value="47.7" lower_limit="36.8" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virological Response at 12 Weeks Post Completion of the Treatment Period (SVR12)</title>
        <description>SVR12 rate for dual therapy participants is defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (&lt;) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [&lt;=] 50 IU/mL) at 12 weeks post completion of the treatment period. If a quantitative test was used, the lower limit of quantification had to be &lt;=50 IU/mL. SVR12 for triple therapy participants is defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection &lt;= 50 IU/mL at 12 weeks post completion of the treatment period.</description>
        <time_frame>12 weeks after end of treatment (up to 118 weeks)</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virological Response at 12 Weeks Post Completion of the Treatment Period (SVR12)</title>
          <description>SVR12 rate for dual therapy participants is defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (&lt;) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [&lt;=] 50 IU/mL) at 12 weeks post completion of the treatment period. If a quantitative test was used, the lower limit of quantification had to be &lt;=50 IU/mL. SVR12 for triple therapy participants is defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection &lt;= 50 IU/mL at 12 weeks post completion of the treatment period.</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2312"/>
                <count group_id="O2" value="496"/>
                <count group_id="O3" value="292"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="821"/>
                <count group_id="O6" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" lower_limit="52.2" upper_limit="56.3"/>
                    <measurement group_id="O2" value="51.0" lower_limit="46.5" upper_limit="55.5"/>
                    <measurement group_id="O3" value="50.0" lower_limit="44.1" upper_limit="55.9"/>
                    <measurement group_id="O4" value="53.8" lower_limit="43.1" upper_limit="64.2"/>
                    <measurement group_id="O5" value="62.0" lower_limit="58.6" upper_limit="65.3"/>
                    <measurement group_id="O6" value="57.0" lower_limit="45.8" upper_limit="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virological Response at Various on Treatment Time Points and End of Treatment (EOT)</title>
        <description>Virological response (VR) for dual therapy participants is defined as HCV RNA &lt;50 IU/mL as assessed by a qualitative HCV RNA test with a lower limit of detection (LLD) &lt;=50 IU/mL or as assessed by a quantitative test with a lower limit of quantification (LLQ) &lt;=50 IU/mL for all time points concerned. Results of HCV RNA tests with LLD and LLQ &gt;50 IU/mL were considered as non-response. VR for triple therapy participants is defined as undetectable HCV RNA assessed by a test with lower limit of detection &lt;=50 IU/mL (UVR). Results of HCV RNA tests with an LLD &gt;50 IU/mL were considered as non-response for triple therapy participants.</description>
        <time_frame>Week 4, 12 and End of treatment (EOT) (up to 96 weeks)</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Virological Response at Various on Treatment Time Points and End of Treatment (EOT)</title>
          <description>Virological response (VR) for dual therapy participants is defined as HCV RNA &lt;50 IU/mL as assessed by a qualitative HCV RNA test with a lower limit of detection (LLD) &lt;=50 IU/mL or as assessed by a quantitative test with a lower limit of quantification (LLQ) &lt;=50 IU/mL for all time points concerned. Results of HCV RNA tests with LLD and LLQ &gt;50 IU/mL were considered as non-response. VR for triple therapy participants is defined as undetectable HCV RNA assessed by a test with lower limit of detection &lt;=50 IU/mL (UVR). Results of HCV RNA tests with an LLD &gt;50 IU/mL were considered as non-response for triple therapy participants.</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2312"/>
                <count group_id="O2" value="496"/>
                <count group_id="O3" value="292"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="821"/>
                <count group_id="O6" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VR by Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" lower_limit="37.5" upper_limit="41.5"/>
                    <measurement group_id="O2" value="40.1" lower_limit="35.8" upper_limit="44.6"/>
                    <measurement group_id="O3" value="9.9" lower_limit="6.8" upper_limit="14.0"/>
                    <measurement group_id="O4" value="9.7" lower_limit="4.5" upper_limit="17.6"/>
                    <measurement group_id="O5" value="49.8" lower_limit="46.3" upper_limit="53.3"/>
                    <measurement group_id="O6" value="51.2" lower_limit="40.1" upper_limit="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VR by Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" lower_limit="69.4" upper_limit="73.2"/>
                    <measurement group_id="O2" value="67.7" lower_limit="63.4" upper_limit="71.8"/>
                    <measurement group_id="O3" value="56.8" lower_limit="51.0" upper_limit="62.6"/>
                    <measurement group_id="O4" value="59.1" lower_limit="48.5" upper_limit="69.2"/>
                    <measurement group_id="O5" value="80.8" lower_limit="77.9" upper_limit="83.4"/>
                    <measurement group_id="O6" value="73.3" lower_limit="62.6" upper_limit="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VR by EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" lower_limit="71.7" upper_limit="75.4"/>
                    <measurement group_id="O2" value="70.6" lower_limit="66.3" upper_limit="74.5"/>
                    <measurement group_id="O3" value="67.1" lower_limit="61.4" upper_limit="72.5"/>
                    <measurement group_id="O4" value="72.0" lower_limit="61.8" upper_limit="80.9"/>
                    <measurement group_id="O5" value="74.9" lower_limit="71.8" upper_limit="77.8"/>
                    <measurement group_id="O6" value="66.3" lower_limit="55.3" upper_limit="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virological Relapse After End of Treatment</title>
        <description>Virological relapse defined as non-virological response (non-VR)/non-undetectable virological response (non-UVR) at the last HCV RNA assessment during the treatment-free follow-up period in participants with VR/UVR at EOT. Here, number of participants analyzed is the participants with end of treatment response (EoT-R) who also had an HCV RNA test at least 12 weeks after EoT or whose last follow-up HCV RNA test showed non-response (HCV RNA &gt;=50 IU/mL).</description>
        <time_frame>Up to 24 weeks after EOT (up to 118 weeks)</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Virological Relapse After End of Treatment</title>
          <description>Virological relapse defined as non-virological response (non-VR)/non-undetectable virological response (non-UVR) at the last HCV RNA assessment during the treatment-free follow-up period in participants with VR/UVR at EOT. Here, number of participants analyzed is the participants with end of treatment response (EoT-R) who also had an HCV RNA test at least 12 weeks after EoT or whose last follow-up HCV RNA test showed non-response (HCV RNA &gt;=50 IU/mL).</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1521"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="581"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="16.5" upper_limit="20.4"/>
                    <measurement group_id="O2" value="19.7" lower_limit="15.5" upper_limit="24.6"/>
                    <measurement group_id="O3" value="21.0" lower_limit="15.3" upper_limit="27.7"/>
                    <measurement group_id="O4" value="20.6" lower_limit="11.5" upper_limit="32.7"/>
                    <measurement group_id="O5" value="13.8" lower_limit="11.1" upper_limit="16.8"/>
                    <measurement group_id="O6" value="7.5" lower_limit="2.1" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virological Breakthrough</title>
        <description>Virological breakthrough/rebound defined as non-VR/non-UVR during the treatment period (including end of treatment) in participants with prior VR/UVR or an increase of HCV RNA by &gt;=1 log10 during the treatment period in comparison to the lowest HCV RNA (nadir) previously measured during the treatment period in participants without VR/UVR during the treatment period. Here, Number of participants analyzed is the participants with at least 2 on-treatment HCV RNA assessments (including EoT) or 1 on-treatment HCV RNA assessment (excluding EoT) and response at EoT by backward imputation.</description>
        <time_frame>Up to EOT (up to 118 weeks)</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Virological Breakthrough</title>
          <description>Virological breakthrough/rebound defined as non-VR/non-UVR during the treatment period (including end of treatment) in participants with prior VR/UVR or an increase of HCV RNA by &gt;=1 log10 during the treatment period in comparison to the lowest HCV RNA (nadir) previously measured during the treatment period in participants without VR/UVR during the treatment period. Here, Number of participants analyzed is the participants with at least 2 on-treatment HCV RNA assessments (including EoT) or 1 on-treatment HCV RNA assessment (excluding EoT) and response at EoT by backward imputation.</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2079"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="275"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="785"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.5" upper_limit="6.4"/>
                    <measurement group_id="O2" value="4.8" lower_limit="3.0" upper_limit="7.3"/>
                    <measurement group_id="O3" value="8.7" lower_limit="5.7" upper_limit="12.7"/>
                    <measurement group_id="O4" value="15.9" lower_limit="9.0" upper_limit="25.2"/>
                    <measurement group_id="O5" value="15.0" lower_limit="12.6" upper_limit="17.7"/>
                    <measurement group_id="O6" value="21.6" lower_limit="12.9" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virological Response (SVR) in Participants With Dose Reductions or Treatment Interruptions</title>
        <description>SVR 12 and 24 rates for dual therapy participants are defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (&lt;) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [&lt;=] 50 IU/mL) at 12 or 24 weeks post completion of the treatment period. If a qualitative test was used, then the lower limit of detection has to be &lt;=50 IU/mL. SVR12 and 24 rates for triple therapy participants are defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection &lt;= 50 IU/mL at 12 or 24 weeks post completion of the treatment period. Here, number of participants analyzed excluded the participants with premature withdrawal due to lack of efficacy or non-safety reasons and participants without dose reductions or interruptions during the first 99 study days.</description>
        <time_frame>Up to first 12 weeks of treatment</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virological Response (SVR) in Participants With Dose Reductions or Treatment Interruptions</title>
          <description>SVR 12 and 24 rates for dual therapy participants are defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (&lt;) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [&lt;=] 50 IU/mL) at 12 or 24 weeks post completion of the treatment period. If a qualitative test was used, then the lower limit of detection has to be &lt;=50 IU/mL. SVR12 and 24 rates for triple therapy participants are defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection &lt;= 50 IU/mL at 12 or 24 weeks post completion of the treatment period. Here, number of participants analyzed excluded the participants with premature withdrawal due to lack of efficacy or non-safety reasons and participants without dose reductions or interruptions during the first 99 study days.</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="79"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR at Week 12 After EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" lower_limit="28.3" upper_limit="46.5"/>
                    <measurement group_id="O2" value="27.3" lower_limit="13.3" upper_limit="45.5"/>
                    <measurement group_id="O3" value="20.7" lower_limit="8.0" upper_limit="39.7"/>
                    <measurement group_id="O4" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O5" value="35.4" lower_limit="25.0" upper_limit="47.0"/>
                    <measurement group_id="O6" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR at Week 24 EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" lower_limit="26.7" upper_limit="44.8"/>
                    <measurement group_id="O2" value="24.2" lower_limit="11.1" upper_limit="42.3"/>
                    <measurement group_id="O3" value="17.2" lower_limit="5.8" upper_limit="35.8"/>
                    <measurement group_id="O4" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O5" value="34.2" lower_limit="23.9" upper_limit="45.7"/>
                    <measurement group_id="O6" value="44.4" lower_limit="13.7" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Very Rapid Virological Response, Rapid Virological Response, Complete Early Virological Response and Partial Early Virological Response (pEVR) During First 12 Weeks</title>
        <description>Percentage of participants with very rapid virological response (VRVR) (defined as VR/UVR by study week 2), rapid virological response (RVR) (defined as VR/UVR by study week 4, but no VRVR), complete early virological response (cEVR) (defined as VR/UVR by study week 12, but no VRVR or RVR) and partial early virological response (pEVR) (defined as a 2 log10 drop of HCV RNA by study week 12, but no VRVR, RVR or cEVR) were reported.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>The data for all of the above mentioned virological responses were not collected and was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Very Rapid Virological Response, Rapid Virological Response, Complete Early Virological Response and Partial Early Virological Response (pEVR) During First 12 Weeks</title>
          <description>Percentage of participants with very rapid virological response (VRVR) (defined as VR/UVR by study week 2), rapid virological response (RVR) (defined as VR/UVR by study week 4, but no VRVR), complete early virological response (cEVR) (defined as VR/UVR by study week 12, but no VRVR or RVR) and partial early virological response (pEVR) (defined as a 2 log10 drop of HCV RNA by study week 12, but no VRVR, RVR or cEVR) were reported.</description>
          <population>The data for all of the above mentioned virological responses were not collected and was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Extended (Rapid) Virological Response (eRVR)</title>
        <description>Extended (rapid) virological response (eRVR) defined as UVR at weeks 4 and 12 for telaprevir, and as UVR at weeks 8 and 24 for boceprevir.</description>
        <time_frame>Up to 98 weeks</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Extended (Rapid) Virological Response (eRVR)</title>
          <description>Extended (rapid) virological response (eRVR) defined as UVR at weeks 4 and 12 for telaprevir, and as UVR at weeks 8 and 24 for boceprevir.</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="821"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" lower_limit="32.1" upper_limit="43.5"/>
                    <measurement group_id="O2" value="32.3" lower_limit="22.9" upper_limit="42.7"/>
                    <measurement group_id="O3" value="45.6" lower_limit="42.1" upper_limit="49.0"/>
                    <measurement group_id="O4" value="47.7" lower_limit="36.8" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Overall Treatment</title>
        <description>Duration of overall treatment was defined as the time between first and last administration of any study drug, in weeks.</description>
        <time_frame>Up to 118 weeks</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Overall Treatment</title>
          <description>Duration of overall treatment was defined as the time between first and last administration of any study drug, in weeks.</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2312"/>
                <count group_id="O2" value="496"/>
                <count group_id="O3" value="292"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="821"/>
                <count group_id="O6" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" spread="16.04"/>
                    <measurement group_id="O2" value="31.3" spread="15.73"/>
                    <measurement group_id="O3" value="35.2" spread="17.48"/>
                    <measurement group_id="O4" value="35.3" spread="15.27"/>
                    <measurement group_id="O5" value="33.2" spread="15.03"/>
                    <measurement group_id="O6" value="31.2" spread="15.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Treated According to Label/Summary of Product Characteristics (SPC)</title>
        <time_frame>Up to 118 weeks</time_frame>
        <population>The data for this outcome measure were not collected and analyzed because the standard of care has changed significantly since the development of the study protocol, this comparison was no longer of practical value.</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Treated According to Label/Summary of Product Characteristics (SPC)</title>
          <population>The data for this outcome measure were not collected and analyzed because the standard of care has changed significantly since the development of the study protocol, this comparison was no longer of practical value.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Discontinued Treatment With PEG-IFN and Ribavirin (RBV)</title>
        <description>Participants who prolonged the treatment period from 72 weeks were not reported.</description>
        <time_frame>Up to 72 weeks of treatment</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Treatment With PEG-IFN and Ribavirin (RBV)</title>
          <description>Participants who prolonged the treatment period from 72 weeks were not reported.</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2312"/>
                <count group_id="O2" value="496"/>
                <count group_id="O3" value="292"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="821"/>
                <count group_id="O6" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued PEG-IFN During Week 1 to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="9.2"/>
                    <measurement group_id="O4" value="9.7"/>
                    <measurement group_id="O5" value="9.9"/>
                    <measurement group_id="O6" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued RBV During Week 1 to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="9.6"/>
                    <measurement group_id="O4" value="10.8"/>
                    <measurement group_id="O5" value="10.8"/>
                    <measurement group_id="O6" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued PEG-IFN During Week 13 to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                    <measurement group_id="O2" value="17.1"/>
                    <measurement group_id="O3" value="16.8"/>
                    <measurement group_id="O4" value="14.0"/>
                    <measurement group_id="O5" value="10.2"/>
                    <measurement group_id="O6" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued RBV During Week 13 to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="22.4"/>
                    <measurement group_id="O3" value="17.1"/>
                    <measurement group_id="O4" value="16.1"/>
                    <measurement group_id="O5" value="13.9"/>
                    <measurement group_id="O6" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued PEG-IFN During Week 25 to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="41.3"/>
                    <measurement group_id="O3" value="30.1"/>
                    <measurement group_id="O4" value="29.0"/>
                    <measurement group_id="O5" value="41.0"/>
                    <measurement group_id="O6" value="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued RBV During Week 25 to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0"/>
                    <measurement group_id="O2" value="46.6"/>
                    <measurement group_id="O3" value="41.1"/>
                    <measurement group_id="O4" value="41.9"/>
                    <measurement group_id="O5" value="44.9"/>
                    <measurement group_id="O6" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued PEG-IFN During Week 49 to Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="32.1"/>
                    <measurement group_id="O3" value="41.1"/>
                    <measurement group_id="O4" value="47.3"/>
                    <measurement group_id="O5" value="38.9"/>
                    <measurement group_id="O6" value="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued RBV During Week 49 to Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="21.0"/>
                    <measurement group_id="O3" value="29.1"/>
                    <measurement group_id="O4" value="31.2"/>
                    <measurement group_id="O5" value="30.3"/>
                    <measurement group_id="O6" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Discontinued Treatment With Direct-Acting Anti-viral (DAA)</title>
        <description>Participants who prolonged the treatment period from 72 weeks were not reported. Participants who discontinued their treatment as planned were included. Here, number of participant analyzed is the total number of participants who received direct-acting anti-viral (DAA).</description>
        <time_frame>Up to 72 weeks of treatment</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Treatment With Direct-Acting Anti-viral (DAA)</title>
          <description>Participants who prolonged the treatment period from 72 weeks were not reported. Participants who discontinued their treatment as planned were included. Here, number of participant analyzed is the total number of participants who received direct-acting anti-viral (DAA).</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="821"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued DAA During Week 1 to Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="7.5"/>
                    <measurement group_id="O3" value="1.7"/>
                    <measurement group_id="O4" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued DAA During Week 3 to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued DAA During Week 5 to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="8.6"/>
                    <measurement group_id="O3" value="24.7"/>
                    <measurement group_id="O4" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued DAA During Week 13 to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="18.3"/>
                    <measurement group_id="O3" value="71.7"/>
                    <measurement group_id="O4" value="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued DAA During Week 25 to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2"/>
                    <measurement group_id="O2" value="64.5"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Concomitant Medical Condition at Baseline</title>
        <time_frame>Baseline</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Concomitant Medical Condition at Baseline</title>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2312"/>
                <count group_id="O2" value="496"/>
                <count group_id="O3" value="292"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="821"/>
                <count group_id="O6" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1"/>
                    <measurement group_id="O2" value="50.4"/>
                    <measurement group_id="O3" value="65.8"/>
                    <measurement group_id="O4" value="68.8"/>
                    <measurement group_id="O5" value="67.2"/>
                    <measurement group_id="O6" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AE)</title>
        <description>An AE was defined as any adverse medical event that occurred after the participant used the investigational medicinal product (IMP) or other intervention behaviors specified by the protocol in the clinical trial regardless of relationship to the study treatment.</description>
        <time_frame>Up to 118 weeks</time_frame>
        <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O2">
            <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O3">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O4">
            <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O5">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
          <group group_id="O6">
            <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
            <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AE)</title>
          <description>An AE was defined as any adverse medical event that occurred after the participant used the investigational medicinal product (IMP) or other intervention behaviors specified by the protocol in the clinical trial regardless of relationship to the study treatment.</description>
          <population>Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2312"/>
                <count group_id="O2" value="496"/>
                <count group_id="O3" value="292"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="821"/>
                <count group_id="O6" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3"/>
                    <measurement group_id="O2" value="65.7"/>
                    <measurement group_id="O3" value="76.7"/>
                    <measurement group_id="O4" value="88.2"/>
                    <measurement group_id="O5" value="90.7"/>
                    <measurement group_id="O6" value="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 118 weeks</time_frame>
      <desc>An AE was defined as any adverse medical event that occurred after the participant used the investigational medicinal product (IMP) or other intervention behaviors specified by the protocol in the clinical trial regardless of relationship to the study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dual Therapy: Peg-IFN Alfa-2a + Ribavirin</title>
          <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2a along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="E2">
          <title>Dual Therapy: Peg-IFN Alfa-2b + Ribavirin</title>
          <description>Participants with CHC receiving dual therapy (peg-IFN Alfa-2b along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="E3">
          <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="E4">
          <title>Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="E5">
          <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
        <group group_id="E6">
          <title>Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin</title>
          <description>Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="163" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired haemophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Eye oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dermo-hypodermitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>End stage AIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Listeria sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Septic arthritis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Streptococcal endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pneumocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>VIIIth nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alpha 1 foetoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Tetany</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Neck mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cardiac myxoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hepatic cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Papillary cystadenoma lymphomatosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Diabetic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Diabetic hyperglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Sensorimotor disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Toxic leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Persecutory delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Excessive granulation tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Vascular purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Victim of homicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Polypectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1225" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="287" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="207" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="79" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="709" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="72" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="435" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="351" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="84" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="94" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="134" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="78" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="245" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="244" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="170" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="97" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="118" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="94" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="100" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="240" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="155" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="2312"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="496"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="292"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="821"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor‚Äôs intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

